IPO registrations (S-1, F-1) · Registrants
Fusion Pharmaceuticals Inc.
- SEC CIK
- 1805890 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-06-05, last 2020-06-24; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2020-06-26; declared effective 2020-06-25
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- Z4
- Business address
- 270 LONGWOOD ROAD SOUTH, Hamilton, A6 L8P 0A6
- EDGAR entity type
- operating
- Insiders and CEO pay
- Fusion Pharmaceuticals Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2020-06-24)
- Final price
- $17.00 per share, above the range (424B4 filed 2020-06-26, an initial public offering)
- Shares sold
- 12,500,000
- Gross proceeds
- $212,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FUSN
- Lead underwriters
- Morgan Stanley; Jefferies; Cowen
- Syndicate
- Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Fusion Pharmaceuticals Inc. EXACT (CIK (EXACT))
- Person page: James J O'Leary Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-06-05 | S-1 | S-1 (registration) | Fusion Pharmaceuticals Inc. | 0001193125-20-162195 ↗ |
| 2020-06-22 | S-1/A | S-1/A (amendment) | Fusion Pharmaceuticals Inc. | 0001193125-20-174636 ↗ |
| 2020-06-24 | S-1/A | S-1/A (amendment) | Fusion Pharmaceuticals Inc. | 0001193125-20-177615 ↗ |
| 2020-06-25 | EFFECT | EFFECT (declared effective) | Fusion Pharmaceuticals Inc. | 9999999995-20-001543 ↗ |
| 2020-06-26 | 424B4 | 424B4 (final prospectus) | Fusion Pharmaceuticals Inc. | 0001193125-20-181060 ↗ |
| 2021-07-13 | EFFECT | EFFECT (declared effective) | Fusion Pharmaceuticals Inc. | 9999999995-21-002745 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-24 | S-1/A | registration statement | $14.00–$16.00 | 12,500,000 | - | Nasdaq FUSN | 4 | primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped, cover names 4 | document ↗ | |
| 2020-06-26 | 424B4 | final prospectus | $17.00 | 12,500,000 | $212,500,000 | Nasdaq FUSN | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ADAMS STREET PARTNERS LLC | TenPercentOwner | 4 | 2020 | ||
| BONDERMAN DAVID | Other; TenPercentOwner | 2 | 2020 | ||
| Burak Eric | Officer | Chief Scientific Officer; Chief? Scientific Officer; Chief Technology Officer | 7 | 2020–2024 | |
| CAGNONI PABLO J | Director | 6 | 2020–2024 | ||
| Christenson Johan | Director | 3 | 2020 | ||
| COULTER JAMES G | Other; TenPercentOwner | 2 | 2020 | ||
| Crowley John J | Officer | Chief Financial Officer | 8 | 2020–2024 | |
| GANNON STEVEN | Director | 10 | 2020–2024 | ||
| HealthCap VII GP S.A. | TenPercentOwner | 2 | 2020 | ||
| HealthCap VII, L.P. | TenPercentOwner | 2 | 2020 | ||
| JOHNSON & JOHNSON | TenPercentOwner | 2 | 2020 | ||
| Johnson & Johnson Innovation - JJDC, Inc. | TenPercentOwner | 2 | 2020 | ||
| Khuong Chau Quang | Director | 7 | 2020–2023 | ||
| Lamb Damian | Director | 2 | 2020 | ||
| O'Leary James J | Officer | Chief Medical Officer | 5 | 2020–2022 | person page Fuzzy |
| ORBIMED ADVISORS LLC | Director | 2 | 2020 | ||
| OrbiMed Capital GP VII LLC | Director | 2 | 2020 | ||
| Preston Heather | Director | 6 | 2020–2023 | ||
| TPG Group Holdings (SBS) Advisors, Inc. | Other; TenPercentOwner | 2 | 2020 | ||
| Valliant John | Director,Officer | Chief Executive Officer | 23 | 2020–2024 | |
| VARIAN MEDICAL SYSTEMS INC | TenPercentOwner | 2 | 2020 | ||
| ORBIMED CAPITAL LLC | Director | 1 | 2020 | ||
| Duncan Barbara Gayle | Director | 6 | 2020–2024 | ||
| Lee Philina | Director | 6 | 2021–2024 | ||
| Bergstrom Donald A | Director | 6 | 2021–2024 | ||
| Rawat Mohit | Officer | President and CBO; President & CBO | 6 | 2021–2024 | |
| Leamon Christopher P | Officer | Chief Scientific Officer | 5 | 2021–2024 | |
| Bobilev Dmitri | Officer | Chief Medical Officer | 4 | 2022–2024 | |
| Bender Jeremy | Director | 3 | 2023–2024 | ||
| Bitetti Teresa Marie | Director | 3 | 2023–2024 | ||
| Meek David D. | Director | 3 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Fusion Pharmaceuticals Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | James J O'Leary | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), A6 first:
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- GENETIC TECHNOLOGIES LTD C3
- MESOBLAST LTD C3
- Ablynx NV C9
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
In other datasets, the same topic (Health) in A6:
- Form D issuer: 12632926 Canada Ltd. (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health